Viewing StudyNCT05574881



Ignite Creation Date: 2024-05-06 @ 6:12 PM
Last Modification Date: 2024-10-26 @ 2:43 PM
Study NCT ID: NCT05574881
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2024-02-26
First Post: 2022-10-05

Brief Title: Dalpiciclib Fulvestrant Trastuzumab and Pertuzumab in HR Positive HER2 Positive Metastatic Breast Cancer
Sponsor: Fudan University
Organization: Fudan University

Conditions & Keywords Data

Conditions:
Name
Breast Cancer
Keywords:
Name View
Dalpiciclib Fulvestrant Trastuzumab and Pertuzumab View
HR positive HER2 positive Metastatic Breast Cancer View